Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Niche, Lackluster: Two Words That Sum Up 2008 NME Launches

Executive Summary

The year 2008 won't go down as the bleakest for new molecular entity drug launches. After all, FDA did approve 24 novel biologics and new molecular entities in 2008, more than in any of the three years prior

You may also be interested in...



2012 Drug Launches Suggest Reasons For Optimism

Launches in 2012 clearly reflect the changes in pharma’s R&D investment priorities in recent years, as the industry has shifted emphasis from primary-care blockbusters to more targeted specialty models. The group includes potential blockbusters like Xeljanz, a dozen novel oncologics, the first new obesity drug in over a decade, and several treatments for rare diseases.

The Year Ahead For Generic Drugs: The Calm Before The Storm

Several blockbuster drugs will face generic competition for the first time in 2010, but overall the year marks a reprieve for brand drug makers, one last chance to grip the ledge before tumbling over the patent cliff in 2011

The Year Ahead For Generic Drugs: The Calm Before The Storm

Several blockbuster drugs will face generic competition for the first time in 2010, but overall the year marks a reprieve for brand drug makers, one last chance to grip the ledge before tumbling over the patent cliff in 2011

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS050535

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel